Literature DB >> 31151895

Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients.

Makoto Mutaguchi1, Makoto Naganuma2, Shinya Sugimoto1, Tomohiro Fukuda1, Kosaku Nanki1, Shinta Mizuno1, Naoki Hosoe3, Masayuki Shimoda4, Haruhiko Ogata3, Yasushi Iwao5, Takanori Kanai6.   

Abstract

BACKGROUND: Although various studies have been conducted on colitis-associated cancer (CAC), few have assessed the differences in the clinical and endoscopic features, treatment, and prognosis of CAC and sporadic neoplasia (SN) in the inflamed mucosa of ulcerative colitis (UC) patients. AIMS: To compare the characteristics of CAC and SN within the previously or currently inflamed mucosa.
METHODS: Between 1997 and 2017, we retrospectively analyzed the endoscopic chart data of 348 colonic lesions from 266 UC patients. Non-dysplastic lesions and lesions located outside the inflamed mucosa were excluded. The diagnosis of CAC or SN was confirmed by conventional histopathological and immunohistochemical evaluation of p53 and Ki67.
RESULTS: In total, 74 patients with CAC (97 lesions) and 46 with SN (58) were enrolled. The proportions of patients with a younger age of onset of UC, with chronic persistent UC, and with severe inflamed mucosa were significantly higher in the CAC group. In the SN group, no flat lesions were found, whereas 26% of the lesions in the CAC group were flat. Sixteen patients died during a median follow-up of 6.1 years (interquartile range (IQR) 1.8-11.1)in the CAC group, whereas 1 patient died during a median follow-up 3.2 years(IQR 1.4-4.6) in the SN group. Mortality from colorectal cancer was significantly higher (P = 0.015) in the CAC group (12/68; 17.6%) than in the SN group (1/44; 2.3%). The 5-year survival rate was 100% in the SN group and 97% in the CAC group for lesions located in the mucosa or submucosa.
CONCLUSION: Recognizing differences in the characteristics of CAC and SN within the inflamed mucosa is critical to avoid unnecessary total colectomy in patients with SN.
Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenoma-Like dysplasia; Colitis-Associated dysplasia; Colorectal cancer; Ulcerative colitis

Mesh:

Year:  2019        PMID: 31151895     DOI: 10.1016/j.dld.2019.05.003

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  4 in total

1.  PRKAR2A-derived circular RNAs promote the malignant transformation of colitis and distinguish patients with colitis-associated colorectal cancer.

Authors:  Daiwei Wan; Sentai Wang; Zhihua Xu; Xinquan Zan; Fei Liu; Ye Han; Min Jiang; Airong Wu; Qiaoming Zhi
Journal:  Clin Transl Med       Date:  2022-02

2.  Surgery for ulcerative colitis complicated with colorectal cancer: when ileal pouch-anal anastomosis is the right choice.

Authors:  Francesco Tonelli; Carmela Di Martino; Andrea Amorosi; Enrico Mini; Gabriella Nesi
Journal:  Updates Surg       Date:  2022-02-25

3.  Diagnostic performance of endoscopic classifications for neoplastic lesions in patients with ulcerative colitis: A retrospective case-control study.

Authors:  Yuichi Kida; Takeshi Yamamura; Keiko Maeda; Tsunaki Sawada; Eri Ishikawa; Yasuyuki Mizutani; Naomi Kakushima; Kazuhiro Furukawa; Takuya Ishikawa; Eizaburo Ohno; Hiroki Kawashima; Masanao Nakamura; Masatoshi Ishigami; Mitsuhiro Fujishiro
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.742

4.  Influence of chronic inflammation on the malignant phenotypes and the plasticity of colorectal cancer cells.

Authors:  Sho Watanabe; Shuji Hibiya; Nobuhiro Katsukura; Sayuki Kitagawa; Ayako Sato; Ryuichi Okamoto; Mamoru Watanabe; Kiichiro Tsuchiya
Journal:  Biochem Biophys Rep       Date:  2021-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.